Soumita Das Selected Research

Soumita Das Research Topics

Disease

22	Infections 05/2024 - 05/2005
18	Inflammation (Inflammations) 03/2024 - 07/2005
9	Neoplasms (Cancer) 08/2023 - 07/2005
8	COVID-19 12/2023 - 01/2021
4	Inflammatory Bowel Diseases (Inflammatory Bowel Disease) 01/2022 - 01/2020
4	Cytokine Release Syndrome 01/2022 - 04/2021
3	Salmonella Infections (Salmonellosis) 05/2024 - 01/2013
3	Colitis 01/2024 - 10/2020
2	Lung Injury 10/2023 - 05/2023
2	Chronic Disease (Chronic Diseases) 08/2023 - 01/2020
2	Sepsis (Septicemia) 08/2023 - 10/2020
2	Interstitial Lung Diseases (Interstitial Lung Disease) 08/2022 - 07/2022
2	Fibrosis (Cirrhosis) 07/2022 - 01/2018
2	Thrombocytopenia (Thrombopenia) 01/2022 - 08/2021
2	Carcinogenesis 10/2020 - 01/2018
2	Diarrhea 01/2020 - 01/2018
2	Cholera 01/2018 - 06/2005
1	Liver Cirrhosis (Hepatic Cirrhosis) 08/2023
1	Crohn Disease (Crohn's Disease) 03/2023
1	Acute Lung Injury 12/2022
1	Pulmonary Fibrosis (Fibrosing Alveolitis) 07/2022
1	Disease Susceptibility (Diathesis) 01/2022
1	Adenoma (Adenomas) 01/2022
1	Hyperplasia 01/2022
1	Communicable Diseases (Infectious Diseases) 12/2021
1	Bacterial Infections (Bacterial Infection) 12/2021
1	Metaplasia 10/2021
1	Fusobacterium Infections 01/2020
1	Colorectal Neoplasms (Colorectal Cancer) 01/2020
1	Microsatellite Instability 01/2020
1	Intestinal Failure 11/2019
1	Shock 01/2018
1	Gastritis 02/2009
1	Persistent Infection 02/2009

Drug/Important Bio-Agent (IBA)

13	Proteins (Proteins, Gene)FDA Link 05/2024 - 05/2005
12	CytokinesIBA 05/2024 - 02/2009
4	DNA Glycosylases (DNA Glycosylase)IBA 12/2023 - 01/2020
4	Interleukin-15 (Interleukin 15)IBA 01/2022 - 04/2021
3	LipopolysaccharidesIBA 03/2024 - 12/2021
3	Dextrans (Dextran)FDA Link 01/2024 - 10/2020
3	sodium sulfate (sodium bisulfate)FDA LinkGeneric 01/2024 - 10/2020
3	Biomarkers (Surrogate Marker)IBA 08/2022 - 01/2020
3	Interleukin-8 (Interleukin 8)IBA 12/2021 - 07/2005
2	ProteomeIBA 05/2024 - 08/2023
2	Antiviral Agents (Antivirals)IBA 10/2023 - 05/2023
2	Lapatinib (GW572016)FDA Link 10/2023 - 05/2023
2	Formaldehyde (Formol)FDA Link 01/2022 - 08/2021
2	AerosolsIBA 12/2021 - 02/2021
2	VaccinesIBA 05/2021 - 01/2021
2	Nicotine FDA Link 02/2021 - 01/2018
2	Enterotoxins (Enterotoxin)IBA 01/2018 - 06/2005
2	Reactive Oxygen Species (Oxygen Radicals)IBA 01/2018 - 01/2016
1	Adenosine Triphosphate (ATP)IBA 05/2024
1	Annexin A1IBA 03/2024
1	EnzymesIBA 01/2023
1	RNA (Ribonucleic Acid)IBA 05/2022
1	Interleukin-13IBA 01/2022
1	Cytoplasmic and Nuclear Receptors (Nuclear Receptors)IBA 01/2022
1	Chloride-Bicarbonate AntiportersIBA 01/2022
1	RNA-Binding Proteins (RNA-Binding Protein)IBA 01/2022
1	Amyloid Precursor Protein Secretases (beta-Secretase)IBA 01/2022
1	Interleukin-6 (Interleukin 6)IBA 12/2021
1	AcidsIBA 10/2021
1	molnupiravirIBA 01/2021
1	Claudin-2IBA 01/2021
1	Peptides (Polypeptides)IBA 01/2021
1	LigandsIBA 01/2021
1	Fatty Acid-Binding ProteinsIBA 10/2020
1	Complement C3 (C3 Complement)IBA 10/2020
1	ErbB Receptors (EGF Receptor)IBA 01/2020
1	Calcibiotic Root Canal SealerIBA 01/2020
1	Erlotinib Hydrochloride (CP 358,774)FDA Link 01/2020
1	AfatinibIBA 01/2020
1	Tyrosine Kinase InhibitorsIBA 01/2020
1	Adenylate KinaseIBA 01/2020
1	CalciumIBA 01/2020
1	Carbachol (Carbastat)FDA Link 01/2020
1	ChloridesIBA 01/2020
1	Epidermal Growth Factor (EGF)IBA 01/2020
1	Tumor Necrosis Factor-alpha (Tumor Necrosis Factor)IBA 01/2020
1	osimertinibIBA 01/2020
1	Epithelial Cell Adhesion MoleculeIBA 11/2019
1	Phosphotransferases (Kinase)IBA 01/2019
1	Tumor Biomarkers (Tumor Markers)IBA 01/2018
1	Caspase 3 (Caspase-3)IBA 01/2018
1	C.I. direct red 80IBA 01/2018
1	E-Cigarette VaporIBA 01/2018
1	Cholera ToxinIBA 01/2018
1	Anti-Bacterial Agents (Antibiotics)IBA 01/2018
1	NucleotidesIBA 01/2018
1	Adenosine Monophosphate (AMP)IBA 01/2018
1	Oxidoreductases (Dehydrogenase)IBA 01/2016
1	Blood Proteins (Serum Proteins)IBA 01/2015
1	Angiogenesis InhibitorsIBA 05/2014
1	Interleukin-33IBA 01/2013
1	Interleukin-10 (Interleukin 10)IBA 01/2013
1	Pattern Recognition ReceptorsIBA 02/2011
1	Adenosine (Adenocard)FDA LinkGeneric 02/2009

Therapy/Procedure

12	Therapeutics 08/2023 - 01/2018
1	Oral Administration 01/2024